Petzold, Golo

[["dc.bibliographiccitation.firstpage","4581"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.editor","Raddatz, Dirk"],["dc.date.accessioned","2022-09-01T09:51:13Z"],["dc.date.available","2022-09-01T09:51:13Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-11T13:15:01Z"],["dc.description.abstract","Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The prevalence in patients with type 2 diabetes mellitus is between 55–80%. The spectrum of NALFD ranges from simple steatosis to aggressive steatohepatitis with potentially progressive liver fibrosis up to cirrhosis and hepatocellular carcinoma. In clinical practice, there are two important aims: First to make the diagnosis of NAFLD, and second, to identify patients with advanced fibrosis, because extent of fibrosis is strongly associated with overall mortality, cardiovascular disease, hepatocellular carcinoma, and extrahepatic malignancy. Histology by liver biopsy can deliver this information, but it is an invasive procedure with rare, but potentially severe, complications. Therefore, non-invasive techniques were developed to stage fibrosis. Ultrasound is the primary imaging modality in the assessment of patients with confirmed or suspected NAFLD. This narrative review focus on different ultrasound methods to detect and graduate hepatic steatosis and to determine grade of fibrosis using elastography-methods, such as transient elastography and 2-dimensional shear wave elastography in patients with NAFLD. Particular attention is paid to the application and limitations in overweight patients in clinical practice. Finally, the role of B-mode ultrasound in NAFLD patients to screen for hepatocellular carcinoma is outlined."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3390/jcm11154581"],["dc.identifier.pii","jcm11154581"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113910"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.title","Role of Ultrasound Methods for the Assessment of NAFLD"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0233811"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Knoop, Richard"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Pilavakis, Yiannis"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.editor","Bonaz, Bruno"],["dc.date.accessioned","2021-04-14T08:25:13Z"],["dc.date.available","2021-04-14T08:25:13Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1371/journal.pone.0233811"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17632"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81557"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1932-6203"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","22"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Gastroenterology"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Rieker, Lisanne"],["dc.contributor.author","Hofer, Johannes"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2022-02-01T10:31:30Z"],["dc.date.accessioned","2022-08-18T12:35:38Z"],["dc.date.available","2022-02-01T10:31:30Z"],["dc.date.available","2022-08-18T12:35:38Z"],["dc.date.issued","2022-01-15"],["dc.date.updated","2022-07-29T12:07:20Z"],["dc.description.abstract","Abstract\r\n \r\n Background\r\n Therapy regimens used in patients with inflammatory Bowel Disease (IBD) have been associated with enhanced risk of viral infections or viral reactivation. Moreover, it is uncertain whether IBD patients have increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or infected patients may have an increased risk for severe coronavirus disease 2019 (Covid-19). Managing severe acute flare in ulcerative colitis during the Covid-19 pandemic is a challenge for clinicians and their patients. The results of the published studies mainly report on the role of the prior medication, but not how to treat severe acute flare of IBD patients with severe Covid-19 pneumonia.\r\n \r\n \r\n Case presentation\r\n We report the case of a 68-year-old patient with a long history of ulcerative colitis. He was initially admitted to an external hospital because of severe acute flare. The initiation of a high-dose oral cortisone therapy did not improve the clinical symptoms. During the inpatient treatment, he was tested positive for SARS-CoV-2. At admission to our hospital the patient showed severe flare of his ulcerative colitis and increased Covid-19 symptoms. A cortisone-refractory course was noticed. After detailed multidisciplinary risk–benefit assessment, we initiated an intravenous tacrolimus therapy and dose of prednisolone was tapered gradually. After clinical response, the therapy was adjusted to infliximab. Additionally, the Covid-19 pneumonia was kept under control despite immunosuppression and the patient could be discharged in clinical remission.\r\n \r\n \r\n Conclusions\r\n This case suggest the use of tacrolimus as a bridging therapeutic option for severe acute, cortisone refractory ulcerative colitis in Covid-19 patients. Nevertheless, the best treatment strategy for IBD patients presenting a flare during the outbreak has yet to be defined. Further data for IBD patients under calcineurin inhibitor therapy are urgently needed."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.citation","BMC Gastroenterology. 2022 Jan 15;22(1):22"],["dc.identifier.doi","10.1186/s12876-022-02094-3"],["dc.identifier.pii","2094"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98879"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112942"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.publisher","BioMed Central"],["dc.relation.eissn","1471-230X"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject","Ulcerative colitis"],["dc.subject","Inflammatory bowel disease"],["dc.subject","Case report"],["dc.subject","Covid-19"],["dc.subject","SARS-CoV-2"],["dc.title","Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","123"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Gastroenterology"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Tsaknakis, Birgit"],["dc.contributor.author","Masri, Rawan"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Kunsch, Steffen"],["dc.date.accessioned","2019-07-09T11:45:36Z"],["dc.date.available","2019-07-09T11:45:36Z"],["dc.date.issued","2018"],["dc.description.abstract","BACKGROUND: The mortality due to hemorrhage of esophageal varices (EV) is still high. The predominant cause for EV is liver cirrhosis, which has a high prevalence in Western Europe. Therefore, non-invasive screening markers for the presence of EV are of interest. Here, we aim to investigate whether non-inflammatory gall bladder wall thickening (GBWT) may serve as predictor for the presence of EV in comparison and combination with other non-invasive clinical and laboratory parameters. METHODS: One hundred ninety four patients were retrospectively enrolled in the study. Abdominal ultrasound, upper endoscopy and blood tests were evaluated. GBWT, spleen size and the presence of ascites were evaluated by ultrasound. Platelet count and Child-Pugh-score were also recorded. The study population was categorized in two groups: 122 patients without esophageal varices (non EV) compared to 72 patients with EV were analyzed by uni-and multivariate analysis. RESULTS: In the EV group 46% showed a non-inflammatory GBWT of ≥4 mm, compared to 12% in the non-EV group (p < 0.01). GBWT was significantly higher in EV patients compared to the non-EV group (mean: 4.4 mm vs. 2.8 mm, p < 0.0001), and multivariate analysis confirmed GBWT as independent predictor for EV (p < 0.04). The platelets/GBWT ratio (cut-off > 46.2) had a sensitivity and specificity of 78 and 86%, PPV 76% and NPV of 87%, and ROC analysis calculated the AUC of 0.864 (CI 0.809-0.919). CONCLUSIONS: GBWT occurs significantly more often in patients with EV. However, because of the low sensitivity, combination with other non-invasive parameters such as platelet count is recommended."],["dc.identifier.doi","10.1186/s12876-018-0852-5"],["dc.identifier.pmid","30071840"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15253"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59263"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","BioMed Central"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Gall bladder wall thickening as non-invasive screening parameter for esophageal varices – a comparative endoscopic – sonographic study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","367"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Ultrasound"],["dc.bibliographiccitation.lastpage","374"],["dc.bibliographiccitation.volume","50"],["dc.contributor.affiliation","Bremer, Sebastian C. B.; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Knoop, Richard F.; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Porsche, Melissa; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Amanzada, Ahmad; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Ellenrieder, Volker; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Neesse, Albrecht; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Kunsch, Steffen; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Porsche, Melissa"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Petzold, Golo"],["dc.date.accessioned","2021-12-01T09:23:12Z"],["dc.date.available","2021-12-01T09:23:12Z"],["dc.date.issued","2021"],["dc.date.updated","2022-06-14T22:49:32Z"],["dc.description.abstract","Abstract Purpose Increased gallbladder wall thickness (GBWT) is a common finding. Reported causes include advanced chronic liver disease (ACLD), ascites and hypalbuminemia. GBWT is a marker for the prediction of esophageal varices. It remains unclear which of these factors is the decisive driver of GBWT. We aim to investigate whether there is a predominant factor associated with the GBWT. Methods We enrolled 258 patients with ascites, hypalbuminemia and/or ACLD and 98 healthy volunteers that underwent abdominal ultrasound. Differences of mean GBWT in subgroups of patients with ACLD, ascites, and/or hypalbuminemia were analyzed. Correlation between various parameters and GBWT were calculated using multiple regression analysis. Results GBWT in patients with ACLD + ascites + hypalbuminemia (n = 59; 5.70 ± 2.05 mm) was pathologically increased compared to patients with hypalbuminemia + ascites without ACLD (n = 36; 2.14 ± 0.66 mm; p < .001) and to patients with only hypalbuminemia (n = 76; 2.02 ± 0.80 mm; p < .001). GBWT of patients with ACLD + hypalbuminemia (n = 30; 3.42 ± 1.52 mm) and with ACLD and normal albumin level were not different (n = 46; 3.10 ± 1.62 mm; p > .999). Significant correlation was seen between GBWT and ACLD (r = .53; p < .001) and ascites (r = .51; p < .001) but not albumin level (r = .04; p = .510). Conclusion We demonstrate that ACLD is predominantly associated with GBWT. In contrast to the current literature, serum albumin level appears not to be associated with pathological GBWT."],["dc.description.abstract","Representative image of a gallbladder of a patient with liver cirrhosis and ascites using a convex transducer (4.0 MHz). The gallbladder wall is pathologically thickened image"],["dc.identifier.doi","10.1002/jcu.23077"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94586"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.publisher","John Wiley & Sons, Inc."],["dc.relation.eissn","1097-0096"],["dc.relation.issn","0091-2751"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited."],["dc.title","Pathological gallbladder wall thickening is associated with advanced chronic liver disease and independent of serum albumin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0223893"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Bathe, Anna Luisa"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.editor","Bonaz, Bruno"],["dc.date.accessioned","2020-12-10T18:42:11Z"],["dc.date.available","2020-12-10T18:42:11Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1371/journal.pone.0223893"],["dc.identifier.eissn","1932-6203"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16609"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77836"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn’s disease and ulcerative colitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e15172"],["dc.bibliographiccitation.firstpage","e15172"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2020-12-10T18:20:07Z"],["dc.date.available","2020-12-10T18:20:07Z"],["dc.date.issued","2019"],["dc.description.abstract","The incidence of inflammatory bowel disease (IBD) is increasing and the pathogenesis is still not completely understood. Micronutrients like vitamin D [25 (OH)D] and zinc play an important role in enzyme activities and the immune system. As the 25 (OH)D-receptor has been shown to be downregulated in patients with IBD, 25 (OH)D may emerge as a predictive marker for disease improvement. Studies on relationship of both micronutrients in IBD patients are lacking.We retrospectively evaluated serum levels of 25(OH)D and zinc together with baseline characteristics of 232 IBD patients. Uni- and multivariate analyses were performed for association between serum levels of 25(OH)D and zinc with clinical and deep remission (CR and DR).155 Crohn's disease (CD) and 77 ulcerative colitis (UC) patients were included. 54% (n = 125) and 6% (n = 14) of IBD patients showed deficient serum 25(OH)D levels below 20 ng/mL and zinc levels below 7 μmol/L. Serum 25(OH)D levels were significantly higher in IBD patients with CR (P = .02) and DR (P < .001) but not serum zinc levels, respectively. Serum 25(OH)D levels (P = .008), anti-tumor-necrosis-factor-α-trough-concentration (anti-TNF-α-TC) (P = .02) and CRP level (P = .02) were independently associated with CR in CD patients. Serum 25(OH)D threshold of 19 ng/mL discriminated CD patients with or without CR, having an area under the receiver operating curve analysis (AUROC) of 0.77 [95%-confidence interval (CI): 0.68-0.85]. In multivariate analysis serum 25(OH)D levels (P = .04) and anti-TNF-α-TC (P = .04) were associated with DR in CD patients. Serum 25(OH)D threshold of 26 ng/mL discriminated CD patients with or without DR, having an AUROC of 0.75 (95%-CI: 0.68-0.83).Serum 25(OH)D (P = .04) and fecal calprotectin levels (P = .04) were independently correlated with CR in UC patients. Serum 25(OH)D threshold of 32 ng/mL discriminated UC patients in CR with an AUROC of 0.83 (95%-CI: 0.71-0.95). Zinc levels did not correlate with disease activity status in CD or UC patients either.In conclusion, beside CRP and fecal calprotectin, serum 25(OH)D levels, but not serum zinc levels, may be an additional useful and noninvasive marker for characterizing different disease activity status of IBD patients. Measurement of serum 25(OH)D in IBD patients may be warranted. 25(OH)D supplementation in deficient IBD patients is recommended."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2019"],["dc.identifier.doi","10.1097/MD.0000000000015172"],["dc.identifier.eissn","1536-5964"],["dc.identifier.issn","0025-7974"],["dc.identifier.pmid","30985701"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16069"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75459"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Serum vitamin D but not zinc levels are associated with different disease activity status in patients with inflammatory bowel disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","BioMed Research International"],["dc.bibliographiccitation.lastpage","6"],["dc.bibliographiccitation.volume","2022"],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Gaertner, Pauline C."],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Kunsch, Steffen"],["dc.date.accessioned","2022-06-01T09:39:38Z"],["dc.date.available","2022-06-01T09:39:38Z"],["dc.date.issued","2022"],["dc.description.abstract","Background and Aims. In contrast to guideline recommendations, endoscopic testing for Helicobacter pylori is frequently performed under Helicobacter pylori suppressive conditions, e.g., intake of proton-pump inhibitors (PPI), preceded antibiotic treatment, or recent gastrointestinal bleeding. Our study\\’s aim was to retest patients with—under suppressive conditions—negative test results. This was carried out in order to examine the rate of false negative tests previously gathered under suppressive conditions. Methods. The trial was conducted in a large patient collective in a university hospital. Every elective esophagogastroduodenoscopy from in- and outpatients was included. Prior to endoscopy, suppressive conditions were collected via standardized questionnaire. If Helicobacter pylori testing was indicated, both helicobacter urease test and histology were performed in analogy to the Sydney classification. In case of a negative result under suppressive conditions, the patient was reinvited after, if possible, withdrawal of suppressive condition in order to perform a urea breath test (UBT). Results. 1,216 patients were included (median 59 years, 72.0% inpatients, 28.0% outpatients). Overall, 60.6% (737) were under Helicobacter pylori suppressive conditions. The main suppressive condition was intake of PPIs (54.5%). In 53.7% (653) of all included cases, Helicobacter pylori testing was performed. Of those, 14.1% (92) had a positive test, and 85.9% (561) were negative. Out of the patients with negative result, 50.8% (285) were tested under suppressive conditions and consequently invited for retesting via UBT. In 20.4% (45), suppressive conditions could not be ceased. In 22.8% (65), retesting was conducted. Of those, 98.5% (64) congruently presented a negative result again, and only 1.5% (1) was positive for Helicobacter pylori. Conclusion. Many patients undergoing esophagogastroduodenoscopy in everyday clinical practice are tested for Helicobacter pylori under suppressive conditions leading to a potentially higher risk of false negative results. However, our research shows that this issue might be overestimated."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1155/2022/5380001"],["dc.identifier.pii","5380001"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108523"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","2314-6141"],["dc.relation.issn","2314-6133"],["dc.rights","CC BY 4.0"],["dc.title","Systematic Retesting for Helicobacter pylori: The Potential Overestimation of Suppressive Conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2926"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Heuschert, Felix C."],["dc.contributor.author","Treiber, Hannes"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Neesse, Albrecht"],["dc.date.accessioned","2021-08-12T07:45:52Z"],["dc.date.available","2021-08-12T07:45:52Z"],["dc.date.issued","2021"],["dc.description.abstract","Treatment of recurrent malignant ascites in cancer patients is a challenge. Evidence based guidelines regarding the best treatment strategy are lacking. The aim of this prospective study was to investigate the safety and efficacy of a tunnelled peritoneal catheter (PleurX) in cancer patients with symptomatic ascites. Patients with symptomatic, diuretics-refractory ascites and indication for the implantation of a tunnelled peritoneal PleurX catheter were prospectively enrolled between August 2018 and July 2020. The number of catheter days, complications, amount of drained ascites and ascites-associated symptoms and hospitalization rate pre- and post-PleurX insertion were analysed. 51 Patients (64.7% male) were prospectively enrolled. The mean age was 66.6 (±7.9) years. The most common cause of ascites was pancreatic adenocarcinoma (n = 10) followed by cholangiocellular carcinoma (n = 9) and hepatocellular carcinoma (n = 8). The technical success rate of PleurX implantation was 100%. The mean volume of weakly drained ascites was 5.44l (±4.08). Major complications included cellulitis (n = 2), peritonitis and drainage dislocation (each n = 1). The mean catheter days per patient was 59.8 (±107.4) (Min 4, Max 668). Abdominal discomfort, impaired mobility, dyspnoea, fatigue, nausea and vomiting were significantly reduced 30 days after PleurX insertion (p < 0.05). Moreover, hospitalization rate was significantly reduced (p < 0.001; 27.08% of days preimplantation vs. 11.27% postimplantation). We conclude that implantation of a tunnelled ascites catheter is a safe and effective method for the treatment of refractory ascites in cancer patients with advanced disease. Serious complications are rare. Burdensome ascites-associated symptoms and hospitalization rates can be significantly reduced over a longer period of time."],["dc.description.abstract","Treatment of recurrent malignant ascites in cancer patients is a challenge. Evidence based guidelines regarding the best treatment strategy are lacking. The aim of this prospective study was to investigate the safety and efficacy of a tunnelled peritoneal catheter (PleurX) in cancer patients with symptomatic ascites. Patients with symptomatic, diuretics-refractory ascites and indication for the implantation of a tunnelled peritoneal PleurX catheter were prospectively enrolled between August 2018 and July 2020. The number of catheter days, complications, amount of drained ascites and ascites-associated symptoms and hospitalization rate pre- and post-PleurX insertion were analysed. 51 Patients (64.7% male) were prospectively enrolled. The mean age was 66.6 (±7.9) years. The most common cause of ascites was pancreatic adenocarcinoma (n = 10) followed by cholangiocellular carcinoma (n = 9) and hepatocellular carcinoma (n = 8). The technical success rate of PleurX implantation was 100%. The mean volume of weakly drained ascites was 5.44l (±4.08). Major complications included cellulitis (n = 2), peritonitis and drainage dislocation (each n = 1). The mean catheter days per patient was 59.8 (±107.4) (Min 4, Max 668). Abdominal discomfort, impaired mobility, dyspnoea, fatigue, nausea and vomiting were significantly reduced 30 days after PleurX insertion (p < 0.05). Moreover, hospitalization rate was significantly reduced (p < 0.001; 27.08% of days preimplantation vs. 11.27% postimplantation). We conclude that implantation of a tunnelled ascites catheter is a safe and effective method for the treatment of refractory ascites in cancer patients with advanced disease. Serious complications are rare. Burdensome ascites-associated symptoms and hospitalization rates can be significantly reduced over a longer period of time."],["dc.identifier.doi","10.3390/cancers13122926"],["dc.identifier.pii","cancers13122926"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88562"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Tunnelled Peritoneal Catheter for Malignant Ascites—An Open-Label, Prospective, Observational Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","552"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Digestion"],["dc.bibliographiccitation.lastpage","556"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Bremer, Sebastian C.B."],["dc.contributor.author","Gress, Thomas M."],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Kunsch, Steffen"],["dc.date.accessioned","2021-04-14T08:32:51Z"],["dc.date.available","2021-04-14T08:32:51Z"],["dc.date.issued","2020"],["dc.description.abstract","Background and Aims: Testing for Helicobacter pylori is frequently conducted during esophagogastroduodenoscopy (EGD). Suppressive conditions such as the intake of proton-pump inhibitors (PPIs), preceded antibiotic treatment or recent upper gastrointestinal bleeding impair H. pylori test quality. The aim of our study was to evaluate the frequency and pattern of H. pylori suppressive conditions in a large patient collective undergoing elective EGD in a German university hospital. Methods: The trial was performed as a single-center study. Only elective EGD from inpatients and outpatients were included. Prior to endoscopy, H. pylori suppressive conditions were collected using a standardized questionnaire. If H. pylori testing was indicated according to the guidelines, always both histology and helicobacter urease test were performed in analogy to the Sydney classification. Results: One thousand six hundred and thirty-one patients were included (median 61 years, 36.0% outpatients, 64.0% inpatients). Overall, 76.5% of patients were under H. pylori suppressive conditions. The main suppressive condition was the intake of PPIs (70.7%). In 819 (50.2%) of all included cases, H. pylori testing was performed. The following were the results: 17.3% (142) had a positive H. pylori testing and 82.7% (677) were negative. Of those with negative result, 70.0% were tested under suppressive conditions. Conclusion: Guidelines recommend H. pylori testing under non-suppressive conditions. However, this does not always meet the clinical practice. Our data show that de facto, many patients undergoing elective EGD are tested for H. pylori under suppressive conditions coming along with a higher risk of potentially false negative results. Particularly, concerning this issue, further research is needed to improve and clarify everyday clinical practice."],["dc.identifier.doi","10.1159/000501270"],["dc.identifier.pmid","31216545"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/84034"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9867"],["dc.relation.issn","0012-2823"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Testing of Helicobacter pylori by Endoscopic Biopsy: The Clinical Dilemma of Suppressive Conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]